What's Happening?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the results of their Phase III OptiTROP-Lung05 study at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated
sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab as a first-line treatment for non-small cell lung cancer (NSCLC) with PD-L1 expression. The study demonstrated significant improvements in progression-free survival (PFS) and overall response rates compared to pembrolizumab alone. The combination therapy showed a median PFS that was not reached, compared to 5.7 months for pembrolizumab alone, and a 12-month PFS rate of 62.4% versus 29.0%. The study also reported a positive trend in overall survival, with a 12-month rate of 80.4% compared to 68.9% for the control group.
Why It's Important?
The findings from the OptiTROP-Lung05 study are significant as they suggest a new potential treatment option for patients with advanced NSCLC, a group that often has limited options. The combination of sac-TMT and pembrolizumab could offer a more effective first-line treatment, potentially improving survival rates and quality of life for patients. The study's results also highlight the potential of antibody-drug conjugates (ADCs) in oncology, particularly in combination with immunotherapies, which could lead to broader applications in other cancer types.
What's Next?
Following the promising results, Kelun-Biotech plans to pursue regulatory approval for sac-TMT in combination with pembrolizumab as a first-line treatment for NSCLC. The company is also conducting additional clinical trials to explore the efficacy of sac-TMT in other cancer types. If approved, this combination therapy could become a new standard of care for NSCLC patients, influencing treatment protocols and potentially leading to further research into ADCs in oncology.
